FDA Announces Proposed Collection of Information for Postmarketing Adverse Event Reporting During Influenza Pandemic

Summary

The Food and Drug Administration (FDA) has submitted a proposed collection of information to the Office of Management and Budget (OMB) for review and clearance, focusing on postmarketing adverse event reporting for medical products and dietary supplements during an influenza pandemic.